|
Match
|
Document |
Document Title |
|
|
US20130273116 |
ANTI-FOULING COMPOSITION COMPRISING AN AEROGEL
The present invention also relates to an anti-fouling composition comprising one or more aerogels. In one embodiment the aerogel encapsulate one or more bioactive agents. The one or more... |
|
|
US20090136477 |
Methods of generating and screening for proteases with altered specificity
Disclosed herein are methods for generating proteases with altered specificity for the target molecules they cleave. The invention further discloses methods of using these proteases to treat... |
|
|
US20080206224 |
MUSCLE CONTRACTION TREATMENT UTILIZING BOTULINUM TOXIN
The invention provides for the use of a botulinum toxin to treat contracture, such as muscle contracture, in patients by transdermal administration of the botulinum toxin. |
|
|
US20070141145 |
HYDROPHOBIC CORE CARRIER COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS, METHODS OF MAKING AND USING THE SAME
The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The... |
|
|
US20070025999 |
TREATMENT WITH ANTI-VEGF ANTIBODIES
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients... |
|
|
US20050147599 |
Medical implants and fibrosis-inducing agents
Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between... |
|
|
US20140099297 |
ACE2 POLYPEPTIDE
The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for... |
|
|
US20130224172 |
METHODS OF TREATING BEHAVIORAL SYMPTOMS OF NEUROLOGICAL AND MENTAL DISORDERS
Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having... |
|
|
US20120244139 |
Modified proteases that inhibit complement activation
Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote... |
|
|
US20100055086 |
Antimicrobial Flush Solutions
The present invention provides antimicrobial solutions that comprise at least one alcohol, at least one antimicrobial agent and at least one chelator and/or anticoagulant. Also provided are... |
|
|
US20090202516 |
INHIBITION AND TREATMENT OF GASTROINTESTINAL BIOFILMS
Orally administered physiologically acceptable anti-biofilm compositions comprising enzymes and if desired additional components such as antimicrobials, antibiotics, antifungals, herbals,... |
|
|
US20070224184 |
Method for treating cellulite
The invention relates to the discovery that collagenase injections are effective in dissolving and lysing the collagenase septa network in the skin that comprises cellulite. As such, the invention... |
|
|
US20070015703 |
ADAMTS13-containing compositions having thrombolytic activity
This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or... |
|
|
US20060142195 |
Non-neurotoxic plasminogen activating factors for treating of stroke
The invention pertains to the use and production of non-neurotoxic plasminogen activating factors e.g. of Desmodus rotundus (DSPA) for the therapeutic treatment of stroke in humans in order to... |
|
|
US20160051472 |
PANCREATIC ENZYME COMPOSITIONS AND METHODS FOR TREATING PANCREATITIS AND PANCREATIC INSUFFICIENCY
Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and... |
|
|
US20140120077 |
Compositions and Methods for Safe Treatment of Rhinitis
Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purified botulinum... |
|
|
US20130230598 |
SUSTAINED-RELEASE COMPOSITION OF DRUGS ENCAPSULATED IN MICROPARTICLES OF HYALURONIC ACID
A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased... |
|
|
US20130095152 |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF COMPLEX REGIONAL PAIN SYNDROME
A therapeutic composition for the treatment of the symptoms of complex regional pain syndrome and a method for preparing the therapeutic composition is disclosed. The therapeutic composition is a... |
|
|
US20080317754 |
Human Osteoclast Derived Cathepsin
Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by... |
|
|
US20070071749 |
TREATMENT WITH ANTI-VEGF ANTIBODIES
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients... |
|
|
US20070071748 |
TREATMENT WITH ANTI-VEGF ANTIBODIES
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients... |
|
|
US20070036754 |
TREATMENT WITH ANTI-VEGF ANTIBODIES
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients... |
|
|
US20070036753 |
TREATMENT WITH ANTI-VEGF ANTIBODIES
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients... |
|
|
US20120207741 |
Enzymes For Pharmaceutical Use
The pharmaceutical use of proteases related to a protease derived from Nocardiopsis sp. NRRL 18262 (SEQ ID NO: 1), optionally in combination with a lipase and/or an amylase. Examples of medical... |
|
|
US20110223149 |
PEPTIDOMIMETIC MACROCYCLES
The present invention provides biologically active peptidomimetic macrocycles with improved properties, such as protease resistance, relative to their corresponding polypeptides. The invention... |
|
|
US20100196445 |
SYSTEMS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS
The invention provides methods and devices for the delivery of therapeutic or biologically active agents to tissue, for example by facilitating the transport of said agents through the skin of a... |
|
|
US20100196347 |
BONE GRAFTS WITH REDUCED PROTEASE ACTIVITY AND METHODS OF SELECTION AND USE
The invention features bone grafts (such as bone allografts) with reduced protease activity. These bone grafts are useful, for example, in conjunction with a polypeptide of interest (such as... |
|
|
US20090317358 |
CHIMERIC PROTEINS WITH CELL-TARGETING SPECIFICITY AND APOPTOSIS-INDUCING ACTIVITIES
The present invention relates to chimeric proteins with cell-targeting specificity and apoptosis-inducing activities. In particular, the invention is illustrated by a recombinant chimeric protein... |
|
|
US20090081184 |
NON-PANCREATIC PROTEASES FOR CONTROLLING PLASMA CHOLECYSTOKININ (CCK) CONCENTRATION AND FOR TREATING PAIN
This invention relates to methods for maintaining the basal level or reducing the level of cholecystokinin (CCK) in blood plasma of a mammal. Additionally, the invention provides methods for... |
|
|
US20080274097 |
BOOSTER FOR THERAPY OF DISEASES WITH ULTRASOUND AND PHARMACEUTICAL LIQUID COMPOSITION CONTAINING THE SAME
A booster comprising a plurality of microbubbles of a gas in a liquid, e.g. about 4×107 cells/ml of microbubbles of a gas having a diameter of 0.1 to 100 μm in a 3 to 5% human serum albumin... |
|
|
US20080166334 |
COMBINATION ENZYME FOR CYSTIC FIBROSIS
A stable preparation of digestive/pancreatic enzymes which can be readily formed into a dosage formulation is provided as a treatment of pancreatic insufficiency in persons having cystic fibrosis.... |
|
|
US20060269539 |
ASP2
ASP2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ASP2 polypeptides and... |
|
|
US20060257390 |
Catheter Composition and Uses Thereof
A composition useful for removal of fibrin-bound blood clots from a catheter comprises water, a fibrinolytically effective amount of a plasminogen activator, and a preservatively effective amount... |
|
|
US20060204488 |
Methods for treating adhesive capsulitis
The invention relates to the discovery that collagenase injections are effective in lyse the collagenous adhesions in the shoulder and treat the disorder, adhesive capsulitis. As such, the... |
|
|
US20060147443 |
Synthetic biomaterials having incorporated therein bioactive factors through enzymatically degradable linkages
Synthetic biomaterials containing bioactive factors or modified bioactive factors that are covalently bound to the synthetic precursor components and/or biomaterials by an enzymatically degradable... |
|
|
US20060034822 |
Hyaluronidase preparation for ophthalmic administration and enzymatic methods for accelerating clearance of hemorrhagic blood from the vitreous body of the eye
A thimerosal-free hyaluronidase preparation wherein the preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,000 MW. Also... |
|
|
US20050148504 |
Cysteine protease inhibitor
This invention relates to a cysteine protease inhibitor comprising casein which is a protein derived from milk, a partial peptide of casein, and/or hydrolysate of casein as an active ingredient.... |
|
|
US20110286995 |
Drug Therapy for Celiac Sprue
Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating... |
|
|
US20110110910 |
Proteases for Pharmaceutical Use
The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from Bacillus licheniformis, which is also designated subtilisin Carlsberg, optionally... |
|
|
US20100135978 |
Proteases for Pharmaceutical Use
The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from Bacillus licheniformis, which is also designated subtilisin Carlsberg, optionally... |
|
|
US20090142329 |
Interleukin-1 Beta Converting Enzyme Like Apoptosis Protease-3 and 4
Disclosed are human interleukin-1 β converting enzyme like apoptosis proteases-3 and 4 and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by... |
|
|
US20080044401 |
DRUG THERAPY FOR CELIAC SPRUE
Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating... |
|
|
US20060269538 |
Serine proteases with altered sensitivity to activity-modulating substances
The present invention provides variants of serine proteases of the S1 class with altered sensitivity to one or more activity-modulating substances. A method for the generation of such proteases is... |
|
|
US20050175581 |
Biological entities and the pharmaceutical and diagnostic use thereof
The present invention provides method for the treatment of a disease by applying a medicament comprising a protease with a defined specificity is capable to hydrolyze specific peptide bonds within... |
|
|
US20050002897 |
Biological entities and the pharmaceutical or diagnostic use thereof
The present invention provides method for the treatment of a disease by applying a medicament comprising a protease with a defined specificity is capable to hydrolyze specific peptide bonds within... |
|
|
US20140302004 |
Triple Acting Antimicrobials That Are Refractory To Resistance Development
Multi-drug resistant superbugs are a persistent problem in modern health care. This invention provides an antimicrobial endolysin-Lysostaphin triple fusion protein, comprising (1) an endolysin... |
|
|
US20100092447 |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF PRION DISEASES
A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable... |
|
|
US20100080787 |
COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AN ENZYME WHICH IS INSOLUBLE IN AN AQUEOUS MEDIUM AS WELL AS ITS USES
The invention relates to a cosmetic or dermopharmaceutical composition, as well as these uses. The invention relates mainly to a cosmetic or dermopharmaceutical composition, notably an... |
|
|
US20080292610 |
Medicaments containing enzymes from ciliates for promoting digestion in digestive disorders
A medicament containing enzymes from ciliates selected from the group consisting of hydrolases, lipases, proteases, amylases, glycosidases, phospholipases, phosphodiesterases, phosphatases. |
|
|
US20080003200 |
GRP78 targeting peptides and methods employing same
The compositions and methods include targeting peptides selective for tissue selective binding, particularly prostate and/or bone cancer, or adipose tissue. The methods may comprise targeting... |